LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 765

Search options

  1. Book ; Online ; E-Book: Innovations in nephrology

    Bezerra da Silva Geraldo / Nangaku, Masaomi

    breakthrough technologies in kidney disease care

    2022  

    Author's details edited by Geraldo Bezerra da Silva and Masaomi Nangaku
    Keywords Nephrology ; Kidneys/Displacement
    Subject code 616.99461
    Language English
    Size 1 online resource (538 pages)
    Publisher Springer
    Publishing place Cham, Switzerland
    Document type Book ; Online ; E-Book
    Note Includes index.
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    ISBN 3-031-11570-8 ; 9783031115691 ; 978-3-031-11570-7 ; 3031115694
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

  2. Article: [Clinical application and future perspectives of HIF-PH inhibitors].

    Nangaku, Masaomi

    Nihon yakurigaku zasshi. Folia pharmacologica Japonica

    2024  Volume 159, Issue 3, Page(s) 157–159

    Abstract: Anemia in chronic kidney disease (CKD) occurs due to insufficient production of erythropoietin to compensate for the decrease in hemoglobin. Anemia in CKD has traditionally been treated with periodic injections of erythropoiesis-stimulating agents (ESAs), ...

    Abstract Anemia in chronic kidney disease (CKD) occurs due to insufficient production of erythropoietin to compensate for the decrease in hemoglobin. Anemia in CKD has traditionally been treated with periodic injections of erythropoiesis-stimulating agents (ESAs), which are recombinant human erythropoietin preparations. Although ESA improved anemia in CKD and dramatically improved the quality of life of patients, there are some patients who are hyporesponsive to ESA, and the use of large doses of ESA in these patients may have a negative impact on patient prognosis. Currently, HIF prolyl hydroxylase (HIF-PH) inhibitors have been approved in Japan as a new treatment for anemia in CKD. HIF-PH inhibitors activate HIF and promote the production of endogenous erythropoietin. The 2019 Nobel Prize in Physiology or Medicine was awarded for groundbreaking research that uncovered the HIF pathway. Because HIF-PH inhibitors improve both erythropoietin production and iron metabolism, they are expected to be effective in treating ESA hyporesponsiveness and solve the inconvenience of injectable preparations. On the other hand, its effects are systemic and multifaceted, and long-term effects must be closely monitored.
    MeSH term(s) Humans ; Anemia/drug therapy ; Anemia/etiology ; Renal Insufficiency, Chronic/drug therapy ; Renal Insufficiency, Chronic/metabolism ; Hypoxia-Inducible Factor-Proline Dioxygenases/antagonists & inhibitors ; Hypoxia-Inducible Factor-Proline Dioxygenases/metabolism ; Erythropoietin/metabolism
    Chemical Substances Hypoxia-Inducible Factor-Proline Dioxygenases (EC 1.14.11.29) ; Erythropoietin (11096-26-7)
    Language Japanese
    Publishing date 2024-05-02
    Publishing country Japan
    Document type Journal Article ; Review ; English Abstract
    ZDB-ID 1097532-9
    ISSN 1347-8397 ; 0015-5691
    ISSN (online) 1347-8397
    ISSN 0015-5691
    DOI 10.1254/fpj.23112
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Global perspective of kidney diseases: Challenges and changes.

    Nangaku, Masaomi

    Nephrology (Carlton, Vic.)

    2023  Volume 28 Suppl 1, Page(s) 5–7

    Abstract: Chronic kidney disease (CKD) is a major public health issue worldwide. Although strategies for prevention, early detection and treatment to reduce the progression of CKD should remain continuous endeavours, public funding for kidney replacement therapy ... ...

    Abstract Chronic kidney disease (CKD) is a major public health issue worldwide. Although strategies for prevention, early detection and treatment to reduce the progression of CKD should remain continuous endeavours, public funding for kidney replacement therapy is urgently needed in low-income countries (LICs) and lower-middle-income countries (LMICs). A multisectoral approach is needed to tackle the global burden of kidney disease. Getting a new drug, from first testing to final approval by a regulatory agency and ultimately to market, is a long, costly and risky process. While clinical trials and research have delivered new therapies and devices to patients with kidney disease during the last decade, there remains a significant residual risk for patients with CKD. Therefore, developing new drugs for better treatment and patient care is essential. For this purpose, the ISN held a consensus meeting entitled 'TRANSFORM; TRAnslational Nephrology Science FOR new Medications', which connected experts in the global kidney community and provided guidance on optimal management of translational animal studies for the development of new drugs to treat kidney diseases.
    MeSH term(s) Humans ; Nephrology ; Renal Insufficiency, Chronic/diagnosis ; Renal Insufficiency, Chronic/epidemiology ; Renal Insufficiency, Chronic/therapy ; Kidney ; Renal Replacement Therapy ; Early Diagnosis
    Language English
    Publishing date 2023-08-03
    Publishing country Australia
    Document type Journal Article
    ZDB-ID 1303661-0
    ISSN 1440-1797 ; 1320-5358
    ISSN (online) 1440-1797
    ISSN 1320-5358
    DOI 10.1111/nep.14200
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Book ; Online ; E-Book: Nephrology and public health worldwide

    Silva Junior, Geraldo B. / Ferreiro Fuentes, Alejandro / Nangaku, Masaomi / Remuzzi, Giuseppe / Ronco, Claudio

    (Contributions to nephrology ; 199)

    2021  

    Author's details Editors: Silva Junior, Geraldo B. (Fortaleza) Ferreiro Fuentes, Alejandro (Montevideo) Nangaku, Masaomi (Tokyo ) Remuzzi, Giuseppe (Bergamo) Ronco, Claudio (Vicenza)
    Series title Contributions to nephrology ; 199
    Collection
    Keywords Nephrology
    Language English
    Size 1 Online-Ressource (viii, 359 Seiten), Illustrationen
    Edition 1. Auflage
    Publisher S. Karger
    Publishing place Basel
    Publishing country Switzerland
    Document type Book ; Online ; E-Book
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    HBZ-ID HT021374733
    ISBN 978-3-318-06937-2 ; 9783318069365 ; 3-318-06937-X ; 3318069361
    DOI 10.1159/isbn.978-3-318-06937-2
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

  5. Article ; Online: Endogenous adenine as a key player in diabetic kidney disease progression: an integrated multiomics approach.

    Hong, Yu Ah / Nangaku, Masaomi

    Kidney international

    2024  Volume 105, Issue 5, Page(s) 918–920

    MeSH term(s) Humans ; Diabetic Nephropathies/etiology ; Adenine ; Multiomics ; Kidney ; Renal Insufficiency, Chronic ; Disease Progression ; Diabetes Mellitus
    Chemical Substances Adenine (JAC85A2161)
    Language English
    Publishing date 2024-02-22
    Publishing country United States
    Document type Journal Article
    ZDB-ID 120573-0
    ISSN 1523-1755 ; 0085-2538
    ISSN (online) 1523-1755
    ISSN 0085-2538
    DOI 10.1016/j.kint.2023.11.033
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Book: Erythropoesis stimulating agents

    Nangaku, Masaomi

    past and future

    (Kidney international : Supplement ; 107)

    2007  

    Author's details guest ed. Masaomi Nangaku
    Series title Kidney international : Supplement ; 107
    Kidney international
    Kidney international ; Supplement
    Collection Kidney international
    Kidney international ; Supplement
    Language English
    Size S25 S. : Ill., graph. Darst.
    Publisher Nature Publ. Group
    Publishing place New York, NY
    Publishing country United States
    Document type Book
    HBZ-ID HT015373328
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  7. Article: [Future perspectives of treatment for anemia in chronic kidney disease (CKD) using hypoxia-inducible factor prolyl hydroxylase inhibitors].

    Nangaku, Masaomi

    Rinsho ketsueki] The Japanese journal of clinical hematology

    2021  Volume 62, Issue 8, Page(s) 938–943

    Abstract: Oxygen biology is currently a focus of intensive scientific research. Three scientists received the Nobel prize in physiology or medicine for their outstanding scientific efforts in revealing the mechanisms of oxygen sensing and defense against hypoxia. ... ...

    Abstract Oxygen biology is currently a focus of intensive scientific research. Three scientists received the Nobel prize in physiology or medicine for their outstanding scientific efforts in revealing the mechanisms of oxygen sensing and defense against hypoxia. Hypoxia is a final common pathway to end-stage kidney disease and plays a crucial role in the pathogenesis of cardiovascular complications. Hypoxia-inducible factors (HIFs) are master regulators of defensive mechanisms against hypoxia. Erythropoietin is one of the main targets of HIFs that enhances oxygen delivery by increasing the production of red blood cells. HIF levels are regulated by HIF-prolyl hydroxylase (HIF-PH) inhibitors, which are now available as a new therapeutic modality against anemia in chronic kidney disease. HIF-PH inhibitors raise some theoretical concerns, but should be noted for their potential organ-protective effects.
    MeSH term(s) Anemia/drug therapy ; Anemia/etiology ; Erythropoietin ; Humans ; Hypoxia ; Prolyl-Hydroxylase Inhibitors/therapeutic use ; Renal Insufficiency, Chronic/complications ; Renal Insufficiency, Chronic/drug therapy
    Chemical Substances Prolyl-Hydroxylase Inhibitors ; Erythropoietin (11096-26-7)
    Language Japanese
    Publishing date 2021-09-08
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 390900-1
    ISSN 0485-1439
    ISSN 0485-1439
    DOI 10.11406/rinketsu.62.938
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Metformin-to use or not to use . . . is that the question?

    Nangaku, Masaomi

    Kidney international

    2020  Volume 98, Issue 5, Page(s) 1105–1107

    MeSH term(s) Humans ; Hypoglycemic Agents/adverse effects ; Metformin/adverse effects ; Renal Insufficiency, Chronic
    Chemical Substances Hypoglycemic Agents ; Metformin (9100L32L2N)
    Language English
    Publishing date 2020-10-30
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 120573-0
    ISSN 1523-1755 ; 0085-2538
    ISSN (online) 1523-1755
    ISSN 0085-2538
    DOI 10.1016/j.kint.2020.07.021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Epigenetic regulation of angiogenesis and ischemic response by long noncoding RNA LEENE in diabetes.

    Mimura, Imari / Nangaku, Masaomi

    Kidney international

    2023  Volume 104, Issue 6, Page(s) 1048–1050

    MeSH term(s) Humans ; Epigenesis, Genetic ; RNA, Long Noncoding/genetics ; Ischemia/genetics ; Morphogenesis ; Diabetes Mellitus/genetics
    Chemical Substances RNA, Long Noncoding
    Language English
    Publishing date 2023-07-05
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 120573-0
    ISSN 1523-1755 ; 0085-2538
    ISSN (online) 1523-1755
    ISSN 0085-2538
    DOI 10.1016/j.kint.2023.06.025
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Founding papers of current nephrology: from acute kidney injury to diabetic kidney disease.

    Nangaku, Masaomi

    Kidney international

    2020  Volume 98, Issue 1, Page(s) 6–9

    MeSH term(s) Acute Kidney Injury/diagnosis ; Acute Kidney Injury/etiology ; Diabetes Mellitus ; Diabetic Nephropathies/diagnosis ; Diabetic Nephropathies/etiology ; Erythropoietin ; Humans ; Kidney ; Nephrology
    Chemical Substances Erythropoietin (11096-26-7)
    Language English
    Publishing date 2020-04-23
    Publishing country United States
    Document type Editorial
    ZDB-ID 120573-0
    ISSN 1523-1755 ; 0085-2538
    ISSN (online) 1523-1755
    ISSN 0085-2538
    DOI 10.1016/j.kint.2020.03.040
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top